keyword
MENU ▼
Read by QxMD icon Read
search

Clinical trial metastatic melanoma

keyword
https://www.readbyqxmd.com/read/29453209/recurrent-epistaxis-leading-to-diagnosis-of-primary-sinonasal-melanoma
#1
Karine Tawagi, Rita Akaraz-Avedissian, Irina Burman-Solovyeva
A 48-year-old man presented to urgent care with recurrent epistaxis over 6 months. Initially, nosebleeds were controlled with packing or cautery. Ultimately, he was referred to ear, nose and throat department and underwent nasal endoscopy which revealed polypoid tissue. A biopsy of the polyp showed non-specific inflammation with no evidence of malignancy. Follow-up maxillofacial CT revealed a large mass lesion in the right maxillary sinus, right nasal fossa, much of the ethmoids and right sphenoid, with destruction of adjacent bony structures...
February 16, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29449192/association-of-body-mass-index-and-outcomes-in-patients-with-metastatic-melanoma-treated-with-targeted-therapy-immunotherapy-or-chemotherapy-a-retrospective-multicohort-analysis
#2
Jennifer L McQuade, Carrie R Daniel, Kenneth R Hess, Carmen Mak, Daniel Y Wang, Rajat R Rai, John J Park, Lauren E Haydu, Christine Spencer, Matthew Wongchenko, Stephen Lane, Dung-Yang Lee, Mathilde Kaper, Meredith McKean, Kathryn E Beckermann, Samuel M Rubinstein, Isabelle Rooney, Luna Musib, Nageshwar Budha, Jessie Hsu, Theodore S Nowicki, Alexandre Avila, Tomas Haas, Maneka Puligandla, Sandra Lee, Shenying Fang, Jennifer A Wargo, Jeffrey E Gershenwald, Jeffrey E Lee, Patrick Hwu, Paul B Chapman, Jeffrey A Sosman, Dirk Schadendorf, Jean-Jacques Grob, Keith T Flaherty, Dana Walker, Yibing Yan, Edward McKenna, Jeffrey J Legos, Matteo S Carlino, Antoni Ribas, John M Kirkwood, Georgina V Long, Douglas B Johnson, Alexander M Menzies, Michael A Davies
BACKGROUND: Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between body-mass index (BMI) and progression-free survival or overall survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy. METHODS: This retrospective study analysed independent cohorts of patients with metastatic melanoma assigned to treatment with targeted therapy, immunotherapy, or chemotherapy in randomised clinical trials and one retrospective study of patients treated with immunotherapy...
February 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29411867/withdrawn-systemic-treatments-for-metastatic-cutaneous-melanoma
#3
REVIEW
Tom Crosby, Reg Fish, Bernadette Coles, Malcolm Mason
BACKGROUND: Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing. Few lasting remissions are achieved and the therapeutic aim remains one of palliation.Many agents are used alone or in combination with varying degrees of toxicity and cost. It is unclear whether evidence exists to support these complex regimens over best supportive care / placebo. OBJECTIVES: To review the benefits from the use of systemic therapies in metastatic cutaneous melanoma compared to best supportive care/placebo, and to establish whether a 'standard' therapy exists which is superior to other treatments...
February 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29409500/autoimmune-comorbidities-in-patients-with-metastatic-melanoma-a-retrospective-analysis-of-us-claims-data
#4
Qiufei Ma, Mark Shilkrut, Zhongyun Zhao, Minming Li, Nicolas Batty, Beth Barber
BACKGROUND: Immunotherapies have advanced the treatment of metastatic melanoma; however, they are associated with immune-related toxicities. Patients with pre-existing autoimmune comorbidities are commonly excluded from clinical trials investigating immunotherapies in metastatic melanoma. Since information on pre-existing autoimmune comorbidities in "real-world" patients with newly diagnosed metastatic melanoma is limited, we sought to estimate the prevalence of autoimmune comorbidities and its change over time...
February 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29409139/withdrawn-chemoimmunotherapy-versus-chemotherapy-for-metastatic-malignant-melanoma
#5
REVIEW
Andre D Sasse, Emma C Sasse, Luciana Go Clark, Otavio Augusto Camara Clark
BACKGROUND: Malignant melanoma, one of the most aggressive of all skin cancers, is increasing in incidence throughout the world. Surgery remains the cornerstone of curative treatment in earlier stages. Metastatic disease is incurable in most affected people, because melanoma does not respond to most systemic treatments. A number of novel approaches are under evaluation and have shown promising results, but they are usually associated with increased toxicity and cost. The combination of chemotherapy and immunotherapy has been reported to improve treatment results, but it is still unclear whether evidence exists to support this choice, compared with chemotherapy alone...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29406396/safety-and-efficacy-of-anti-pd-1-therapy-for-metastatic-melanoma-and-non-small-cell-lung-cancer-in-patients-with-viral-hepatitis-a-case-series
#6
Anita Kothapalli, Muhammad A Khattak
Anti-PD-1 monoclonal antibodies have shown durable long-term survival benefit in patients with metastatic melanoma. Limited evidence exists on the safety and efficacy of PD-1 inhibitors in patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections as these patients have traditionally been excluded from clinical trials because of a theoretical risk of immune reconstitution inflammatory syndrome. We aim to determine the safety and efficacy of treatment with PD-1 inhibitors in seven patients with HBV/HCV infection and concurrent metastatic melanoma or non-small-cell lung cancer (NSCLC)...
February 5, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29405038/systemic-treatments-for-metastatic-cutaneous-melanoma
#7
REVIEW
Sandro Pasquali, Andreas V Hadjinicolaou, Vanna Chiarion Sileni, Carlo Riccardo Rossi, Simone Mocellin
BACKGROUND: The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is generally poor. Recently, new classes of drugs (e.g. immune checkpoint inhibitors and small-molecule targeted drugs) have significantly improved patient prognosis, which has drastically changed the landscape of melanoma therapeutic management. This is an update of a Cochrane Review published in 2000. OBJECTIVES: To assess the beneficial and harmful effects of systemic treatments for metastatic cutaneous melanoma...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29390382/brain-metastasis-in-a-patient-with-melanoma-receiving-pembrolizumab-therapy-a-case-report-and-review-of-the-literature
#8
Jin-Cheng Song, Xiao-Lei Ding, Xiu-Hua Sun, Mohammed Safi, Juan Tian
RATIONALE: Melanoma with brain metastasis is associated with a poor prognosis and high mortality rate. As patients with this condition have been excluded from most clinical trials, data on the use of anti-programmed death 1 therapy for these patients are limited. PATIENT CONCERNS: The patient was a 62-year-old man with a 10-year history of melanotic nevus in his right forearm. He was admitted to another hospital in August 2015 due to the growth of the melanotic nevus over 1 year and complaint of a mass in the right mid-axillary area...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29387478/retrospective-review-of-metastatic-melanoma-patients-with-leptomeningeal-disease-treated-with-intrathecal-interleukin-2
#9
Isabella C Glitza, Michelle Rohlfs, Nandita Guha-Thakurta, Roland L Bassett, Chantale Bernatchez, Adi Diab, Scott E Woodman, Cassian Yee, Rodabe N Amaria, Sapna P Patel, Hussein Tawbi, Michael Wong, Wen-Jen Hwu, Patrick Hwu, Amy Heimberger, Ian E McCutcheon, Nicholas Papadopoulos, Michael A Davies
Objectives: Metastatic melanoma patients with leptomeningeal disease (LMD) have an extremely poor prognosis, with a median survival measured in weeks, and few treatment options. Outcomes of a retrospective cohort of patients with LMD that were treated with intrathecal interleukin-2 (IT IL-2) were reviewed to assess the long-term efficacy of this therapy. Methods: The records of metastatic melanoma patients with LMD who were treated with IT IL-2 from 2006 to 2014 in a Compassionate Investigational New Drug study were reviewed...
2018: ESMO Open
https://www.readbyqxmd.com/read/29373180/immunotherapy-an-evolving-approach-for-the-management-of-triple-negative-breast-cancer-converting-non-responders-to-responders
#10
REVIEW
Mai F Tolba, Hany A Omar
Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were first approved by the Food and Drug Administration (FDA) for the management of metastatic melanoma in 2011. The approval of this class is being extended to include other types of immunogenic tumors. Although breast cancer (BC) was first categorized as non-immunogenic tumor type, there are certain subsets of BC that showed a high level of tumor infiltrating lymphocytes (TILs)...
January 12, 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29362221/ccl20-expression-by-tumor-associated-macrophages-predicts-progression-of-human-primary-cutaneous-melanoma
#11
Rafael Samaniego, Alejandra Gutierrez-Gonzalez, Alba Gutierrez-Seijo, Sandra Sanchez-Gregorio, Jorge García-Gimenez, Enrique Mercader, Ivan Marquez-Rodas, Jose Antonio Aviles, Miguel Relloso, Paloma Sanchez-Mateos
The chemokine axis CCR6/CCL20 is involved in cancer progression in a variety of tumors. Here we show that CCR6 is expressed by melanoma cells. The CCR6 ligand, CCL20, induces migration and proliferation in vitro, and enhances tumor growth and metastasis in vivo. Confocal analysis of melanoma tissues showed that CCR6 is expressed by tumor cells, whereas CCL20 is preferentially expressed by non-tumoral cells in the stroma of certain tumors. Stromal CCL20, but not tumoral CCR6, predicted poor survival in a cohort of 40 primary melanoma patients...
January 23, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29361469/patients-with-melanoma-treated-with-an-anti-pd-1-antibody-beyond-recist-progression-a-us-food-and-drug-administration-pooled-analysis
#12
Julia A Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B Goldberg, Meredith K Chuk, Dow-Chung Chi, Jennie Chang, Amy Barone, Sanjeeve Balasubramaniam, Gideon M Blumenthal, Patricia Keegan, Richard Pazdur, Marc R Theoret
BACKGROUND: Patients who receive immunotherapeutic drugs might develop an atypical response pattern, wherein they initially meet conventional response criteria for progressive disease but later have decreases in tumour burden. Such responses warrant further investigation into the potential benefits and risks for patients who continue immunotherapy beyond disease progression defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. METHODS: For this pooled analysis, we included all submissions of trial reports and data to the US Food and Drug Administration (FDA) in support of marketing applications for anti-programmed death receptor-1 (PD-1) antibodies (alone or in combination) for the treatment of patients with unresectable or metastatic melanoma that allowed for continuation of the antibody beyond RECIST-defined progression in the anti-PD-1 group and were approved by FDA before Jan 1, 2017...
January 17, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29356791/success-of-rechallenging-dabrafenib-and-trametinib-combination-therapy-after-trametinib-induced-rhabdomyolysis-a-case-report
#13
Yusuke Muto, William Ng, Kenjiro Namikawa, Akira Takahashi, Arata Tsutsumida, Makiko Nishida, Naoya Yamazaki
The mitogen-activated protein kinase pathway regulates cell growth and differentiation and is activated by BRAF mutations. BRAF mutations are present in about 40-50% of cutaneous melanomas. More than 90% of BRAF mutations are the V600E type. BRAF inhibitor (dabrafenib or vemurafenib) and MEK inhibitor (trametinib or cobimetinib) combination therapies are effective for BRAF-mutant advanced melanomas. A variety of side effects have been observed with combination therapy including pyrexia, fatigue, nausea, and vomiting...
January 29, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29341833/immune-modified-response-evaluation-criteria-in-solid-tumors-imrecist-refining-guidelines-to-assess-the-clinical-benefit-of-cancer-immunotherapy
#14
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S Chen, Jedd D Wolchok
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29341162/impact-of-genomics-on-the-surgical-management-of-melanoma
#15
REVIEW
P M Ferguson, G V Long, R A Scolyer, J F Thompson
BACKGROUND: Although surgery for early-stage melanoma offers the best chance of cure, recent advances in molecular medicine have revolutionized the management of late-stage melanoma, leading to significant improvements in clinical outcomes. Research into the genomic drivers of disease and cancer immunology has not only ushered in a new era of targeted and immune-based therapies for patients with metastatic melanoma, but has also provided new tools for monitoring disease recurrence and selecting therapeutic strategies...
January 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29336323/nivolumab-for-recurrent-cutaneous-squamous-cell-carcinoma-three-cases
#16
Veronika Blum, Beat Müller, Silvia Hofer, Esther Pardo, Kristin Zeidler, Joachim Diebold, Klaus Strobel, Christoph Brand, Stefan Aebi, Oliver Gautschi
Programmed cell death ligand 1 (PD-L1) is frequently expressed in cutaneous squamous cell cancer (CSCC) and preliminary data from an ongoing clinical trial suggest that programmed death receptor 1 (PD-1) checkpoint inhibitors may be useful to treat patients with metastatic non-melanoma skin cancer. To report a series of three patients with advanced CSCC treated with nivolumab, showing that commercially available PD-1 checkpoint inhibitors may be useful in non-melanoma skin cancer patients without access to a clinical trial...
January 16, 2018: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29324592/frequent-subclinical-macular-changes-in-combined-braf-mek-inhibition-with-high-dose-hydroxychloroquine-as-treatment-for-advanced-metastatic-braf-mutant-melanoma-preliminary-results-from-a-phase-i-ii-clinical-treatment-trial
#17
Akosua A Nti, Leona W Serrano, Harpal S Sandhu, Katherine E Uyhazi, Ilaina D Edelstein, Elaine J Zhou, Scott Bowman, Delu Song, Tara C Gangadhar, Lynn M Schuchter, Sheryl Mitnick, Alexander Huang, Charles W Nichols, Ravi K Amaravadi, Benjamin J Kim, Tomas S Aleman
PURPOSE: To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma. METHODS: Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31-68 years of age) were included. Treatment was with oral dabrafenib, 150 mg bid, trametinib, 2 mg/day, and HCQ, 400 mg to 600 mg bid. An ophthalmic examination, spectral domain optical coherence tomography, near-infrared and short-wavelength fundus autofluorescence, and static perimetry were performed at baseline, 1 month, and q/6 months after treatment...
January 10, 2018: Retina
https://www.readbyqxmd.com/read/29306769/phase-ii-trial-of-ipilimumab-in-melanoma-patients-with-preexisting-humoural-immune-response-to-ny-eso-1
#18
G M Haag, I Zoernig, J C Hassel, N Halama, J Dick, N Lang, L Podola, J Funk, C Ziegelmeier, S Juenger, M Bucur, L Umansky, C S Falk, A Freitag, I Karapanagiotou-Schenkel, P Beckhove, A Enk, D Jaeger
BACKGROUND: Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. PATIENTS AND METHODS: Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks...
January 4, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29273043/psychometric-properties-of-the-fact-m-questionnaire-in-patients-with-merkel-cell-carcinoma
#19
REVIEW
Murtuza Bharmal, Fatoumata Fofana, Carla Dias Barbosa, Paul Williams, Lisa Mahnke, Alexia Marrel, Michael Schlichting
BACKGROUND: No validated disease-specific questionnaires exist to capture health-related quality of life (HRQoL) in patients with Merkel cell carcinoma (MCC). The Functional Assessment of Cancer Therapy - Melanoma (FACT-M) is validated in patients with melanoma, which shares many similarities with MCC. This paper reports the psychometric properties of the FACT-M in the metastatic MCC population. METHODS: Data were collected as part of a single-arm, open-label, multicenter trial involving patients with metastatic MCC who had failed at least one previous line of chemotherapy...
December 22, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29239192/-combined-regimens-in-immunotherapy
#20
B Melichar, M Spisarová
The advent of immunotherapy has changed our concept of how to manage metastatic disease. With the exception of relatively rare tumors, the treatment of metastatic cancer is still considered as palliative, and in systemic treatment immunotherapy is often selected, considering better tolerance. Immunotherapy opens the perspective of a long-term, possibly durable, response, and, in contrast to other approaches to targeted therapy, is active across a spectrum of tumors. Combined regimens that increase the efficacy, given the context, are thus of importance...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
keyword
keyword
61074
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"